newsfilter
← Latest News
GlobeNewswire·

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

  • Annovis Bio, Inc. (NYSE: ANVS) announced that CEO Maria Maccecchini, PhD will present at two industry events in November 2026.
  • Dr. Maccecchini will participate in a panel titled "Bridging the Translational Gap: From Discovery Insights to Clinical Proof" & deliver a company showcase at U.S. Biotech Day 2026 on November 16 in Philadelphia.
  • The U.S. Biotech Day panel discussion will feature leaders from Pfizer, Merck, Bristol Myers Squibb, Boehringer Ingelheim, & other pharmaceutical companies.
  • Dr. Maccecchini will present "Restoring Proteostasis in Alzheimer's and Parkinson's Diseases with Buntanetap" at the Pharma Partnering Summit 2026 on November 19 in Boston.
  • At both events, Dr. Maccecchini will hold one-on-one meetings with industry leaders via the events' partnering systems or by contacting ir@annovisbio.com.
  • Annovis is a Phase 3 clinical-stage company developing buntanetap, an investigational oral therapy targeting neurodegenerative diseases including Alzheimer's & Parkinson's.
  • Buntanetap works by inhibiting the translation of multiple neurotoxic proteins such as APP, amyloid beta, tau, alpha-synuclein, & TDP-43 through an RNA-targeting mechanism.
  • The company aims to halt neurodegeneration progression & improve cognitive & motor functions by addressing underlying disease causes.
  • Investors are encouraged to register for email alerts at the company website to receive press releases & industry updates.
  • The press release includes forward-looking statements subject to risks outlined in the company's SEC filings under Form 10-K & Form 10-Q.